Investigating the role autoantibodies play among Native Hawaiians and other Pacific Islanders in increased severity of COVID-19

Simple item page
dc.contributor.advisorChing, Lauren L.
dc.contributor.advisorTseng, Alanna C.
dc.contributor.advisorChang, Sandra
dc.contributor.authorHardisty, Sabrina
dc.contributor.instructorNerurkar, Vivek R.
dc.contributor.instructorSy, Angela
dc.date.accessioned2021-08-27T23:52:11Z
dc.date.available2021-08-27T23:52:11Z
dc.date.issued2021-08-13
dc.description.abstract<p>Background: In Hawaii, the Native Hawaiian and other Pacific Islander (NHPI) communities have reported the highest rates of COVID-19. NHPI populations experience higher rates of autoimmune diseases such as type 1 diabetes, systemic lupus erythematosus, and rheumatoid arthritis, which are linked to increased production of autoantibodies, antibodies that target self-antigens and interfere with the typical immune response. Further, increased autoantibody production has been associated with increased disease severity in COVID-19.<p/> <p>Objective: To investigate the relationship between autoantibodies and SARS-CoV-2 infection among NHPI<p/> <p>Hypothesis: NHPI have an increased tendency to produce autoantibodies upon SARS-CoV-2 infection due to their greater predisposition to develop autoimmunity as compared to non-NHPI.<p/> <p>Methods: Using Luminex-based assay, we evaluated a panel of 20 autoantibodies associated with autoimmune diseases in 152 blood samples collected from naturally infected (NI) and/or vaccinated (VX) NHPI (n=58) and non-NHPI (n=94), and negative controls (NEG), (n=14).<p/> <p>Results: Several autoantibodies were detected in subjects who were NI with SARS-CoV-2. There were no differences in the autoantibody levels between NHPI and non-NHPI. Interestingly, SARS-CoV-2 naive VX individuals, both NHPI and non-NHPI, had a reduced tendency to produce autoantibodies, and this was even lower than control subjects (NEG).<p/> <p>Conclusions: The data did not support our initial hypothesis that NHPI produced higher levels of autoantibodies compared to non-NHPI after COVID-19 infection. However, the reduced levels of autoantibodies detected in both NHPI and non-NHPI vaccinated individuals against COVID-19 suggest that vaccination dampens the production of autoantibodies. Individuals who have been previously infected with SARS-CoV-2, however, do not see these same benefits after subsequent vaccination. Natural infection with SARS-COV-2 appears to increase autoantibody production in all ethnicities. Therefore, NHPI, who are predisposed to developing autoimmune diseases, pose an even greater benefit from COVID-19 vaccination.<p/>
dc.description.sponsorshipNIMHD/NIH-T37MD008636-08; COBRE/NIGMS/NIH-P30GM114737; NIGMS/NIH-3P30GM114737-05S1; INBRE/NIGMS/NIH-P30GM103466-20S1; Ola Hawaii NIMHD/NIH-U54MD007601
dc.identifier.urihttp://hdl.handle.net/10125/76032
dc.language.isoen-US
dc.rightsAttribution-NoDerivs 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by-nd/3.0/us/*
dc.subjectAutoantibodies
dc.subjectPacific Islanders
dc.subjectCOVID-19 (Disease)
dc.subjectHawaiians
dc.titleInvestigating the role autoantibodies play among Native Hawaiians and other Pacific Islanders in increased severity of COVID-19
dc.typeImage
dc.typePresentation
dc.type.dcmiText

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Sabrina Hardisty MHRT 2021 Poster FINAL VRN.pdf
Size:
11.25 MB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.73 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

MHRT Poster Session 2021